30276272|t|Biomarkers for acute diagnosis and management of stroke in neurointensive care units.
30276272|a|The effectiveness of current management of critically ill stroke patients depends on rapid assessment of the type of stroke, ischemic or hemorrhagic, and on a patient's general clinical status. Thrombolytic therapy with recombinant tissue plasminogen activator (r-tPA) is the only effective treatment for ischemic stroke approved by the Food and Drug Administration (FDA), whereas no treatment has been shown to be effective for hemorrhagic stroke. Furthermore, a narrow therapeutic window and fear of precipitating intracranial hemorrhage by administering r-tPA cause many clinicians to avoid using this treatment. Thus, rapid and objective assessments of stroke type at admission would increase the number of patients with ischemic stroke receiving r-tPA treatment and thereby, improve outcome for many additional stroke patients. Considerable literature suggests that brain-specific protein biomarkers of glial [i.e. S100 calcium-binding protein B (S100B), glial fibrillary acidic protein (GFAP)] and neuronal cells [e.g., ubiquitin C-terminal hydrolase-L1 (UCH-L1), neuron-specific enolase (NSE), alphaII-spectrin breakdown products SBDP120, SBDP145, and SBDP150, myelin basic protein (MBP), neurofilament light chain (NF-L), tau protein, visinin-like protein-1 (VLP 1), NR2 peptide] injury that could be detected in the cerebrospinal fluid (CSF) and peripheral blood might provide valuable and timely diagnostic information for stroke necessary to make prompt management and decisions, especially when the time of stroke onset cannot be determined. This information could include injury severity, prognosis of short-term and long-term outcomes, and discrimination of ischemic or hemorrhagic stroke. This chapter reviews the current status of the development of biomarker-based diagnosis of stroke and its potential application to improve stroke care.
30276272	49	55	stroke	Disease	MESH:D020521
30276272	144	150	stroke	Disease	MESH:D020521
30276272	151	159	patients	Species	9606
30276272	203	209	stroke	Disease	MESH:D020521
30276272	211	219	ischemic	Disease	MESH:D002545
30276272	223	234	hemorrhagic	Disease	MESH:D006470
30276272	245	252	patient	Species	9606
30276272	391	406	ischemic stroke	Disease	MESH:D002544
30276272	515	533	hemorrhagic stroke	Disease	MESH:D000083302
30276272	602	625	intracranial hemorrhage	Disease	MESH:D020300
30276272	743	749	stroke	Disease	MESH:D020521
30276272	797	805	patients	Species	9606
30276272	811	826	ischemic stroke	Disease	MESH:D002544
30276272	902	908	stroke	Disease	MESH:D020521
30276272	909	917	patients	Species	9606
30276272	1006	1036	S100 calcium-binding protein B	Gene	6285
30276272	1038	1043	S100B	Gene	6285
30276272	1046	1077	glial fibrillary acidic protein	Gene	2670
30276272	1079	1083	GFAP	Gene	2670
30276272	1112	1145	ubiquitin C-terminal hydrolase-L1	Gene	7345
30276272	1147	1153	UCH-L1	Gene	7345
30276272	1156	1179	neuron-specific enolase	Gene	2026
30276272	1181	1184	NSE	Gene	2026
30276272	1187	1203	alphaII-spectrin	Gene	6709
30276272	1254	1274	myelin basic protein	Gene	4155
30276272	1276	1279	MBP	Gene	4155
30276272	1282	1307	neurofilament light chain	Gene	4747
30276272	1309	1313	NF-L	Gene	4747
30276272	1316	1319	tau	Gene	4137
30276272	1329	1351	visinin-like protein-1	Gene	7447
30276272	1353	1358	VLP 1	Gene	7447
30276272	1519	1525	stroke	Disease	MESH:D020521
30276272	1605	1611	stroke	Disease	MESH:D020521
30276272	1758	1788	ischemic or hemorrhagic stroke	Disease	MESH:D002543
30276272	1881	1887	stroke	Disease	MESH:D020521
30276272	1929	1935	stroke	Disease	MESH:D020521
30276272	Association	MESH:D020521	2670
30276272	Association	MESH:D002543	7447
30276272	Association	MESH:D020521	6709
30276272	Association	MESH:D020521	4137
30276272	Association	MESH:D020521	2026
30276272	Association	MESH:D020521	4155
30276272	Association	MESH:D020521	6285
30276272	Association	MESH:D002543	6709
30276272	Association	MESH:D020521	7345
30276272	Association	MESH:D020521	7447
30276272	Association	MESH:D020521	4747

